Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Chang-Douglass
Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Palbociclib Plus Letrozole Versus Letrozole Alone as a First-Line Treatment in Women With Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer. Revised Results for the Swiss Health Care Setting
Breast Cancer Research and Treatment
Cancer Research
Oncology
Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis
OncoTargets and Therapy
Oncology
Pharmacology
Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
